LLY Eli Lilly and Company

121.85
+0.15  (+0%)
Previous Close 121.7
Open 121.98
Price To Book 34.62
Market Cap 116,991,934,446
Shares 960,130,771
Volume 247,451
Short Ratio 3.46
Av. Daily Volume 3,127,641
Stock charts supplied by TradingView

NewsSee all news

  1. Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure

    RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 13, 2019 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) announced today results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to

  2. CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

    INDIANAPOLIS, Dec. 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion

  3. Lilly Opens First Ever Randomized Phase 3 Clinical Trial in Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer

    INDIANAPOLIS, Dec. 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the opening of the LIBRETTO-431 clinical trial [NCT04194944] for selpercatinib, also known as LOXO-292, for treatment-naïve RET

  4. Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting

    INDIANAPOLIS, Dec. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced interim clinical data from the LOXO-305 global Phase 1/2 BRUIN dose escalation trial. LOXO-305 is an investigational, highly

  5. Lilly Announces New Leadership and Strategy in Oncology Research and Development

    INDIANAPOLIS, Dec. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced new leadership and strategic direction in oncology R&D, combining the Lilly Research Laboratories (LRL) oncology

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 BREEZE-AD7 trial met primary endpoint - August 23, 2019.
Baricitinib
Atopic dermatitis
NDA filing due YE 2019.
LOXO-292
RET-fusion non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other tumors
FDA approval (label expansion) announced June 5, 2018.
KEYTRUDA + chemo (KEYNOTE-021)
First-Line Nonsquamous Non-small cell lung cancer (NSCLC)
FDA approval announced September 27, 2018.
Galcanezumab - EVOLVE-1, EVOLVE-2 and REGAIN
Migraine prevention
FDA Approval announced October 11, 2019.
Lasmiditan
Migraine
FDA label expansion announced January 31, 2019.
(MK-3475-189/KEYNOTE-189)
First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3 data released February 19, 2019. 10mg dose met primary endpoint. 5mg dose did not meet endpoint.
Tanezumab
Chronic low back pain
Phase 3 trial met primary endpoint - noted October 2, 2018.
Ultra rapid insulin
Diabetes
Phase 3 data from second trial released January 29, 2019 - co-primary endpoints met. Data from trial April 18, 2019 met 2/3 primary endpoints in 5mg arm but failed to meet endpoints in 2.5mg arm. Regulatory filing due 4Q 2019 or early 2020.
Tanezumab
Osteoarthritis
Phase 3 data due 1H 2020.
Tanezumab
Cancer pain
Phase 3 PFS data met primary endpoint but overall survival not improved. Will not seek regulatory approval.
Ramucirumab - RAINFALL
First-line gastric cancer
Phase 3 trial met primary endpoints - September 5, 2018.
Flortaucipir F 18 (Tau imaging agent)
Alzheimer's disease
Phase 3 data did not meet primary endpoint - December 13, 2019.
Empagliflozin
Heart failure with preserved ejection fraction (HFpEF)
Phase 3 data did not meet primary endpoint - December 13, 2019.
Empagliflozin
Heart failure with reduced ejection fraction (HFrEF)
Approval announced February 26, 2018.
Abemaciclib - MONARCH 3
HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC)
Approved October 4, 2017.
Abemaciclib - MONARCH 1 and 2
Second-line hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer and HR+, HER2- breast cancer
Phase 3 data released October 10, 2017 - primary endpoint not met.
Abemaciclib - JUNIPER
Thrid line KRAS mutation positive Non-small cell lung cancer (NSCLC)
Approval announced December 1, 2017.
Taltz
Psoriatic Arthritis
CRL received April 14, 2017. NDA resubmitted. Approval announced for low dose only - June 1, 2018.
Baricitinib
Rheumatoid arthritis
FDA Approval announced November 26, 2018.
Larotrectinib (LOXO-101)
Solid tumors that harbor a TRK fusion.
Phase 3 trial met primary endpoint - noted June 25, 2018.
Empagliflozin
Type 1 Diabetes
Announced discontinuation of trial due to futility - June 12, 2018.
Lanabecestat (AZD3293) - AMARANTH
Early Alzheimer's disease
FDA approval announced May 13, 2019.
Ramucirumab REACH-2
Hepatocellular Carcinoma
Phase 3 PFS primary endpoint met - March 12, 2019.
Ramucirumab
Non-small cell lung cancer
FDA Approval announced August 26, 2019.
Ixekizumab
Axial Spondyloarthritis
Phase 3 trial met primary endpoint - July 19, 2018.
Tradjenta (linagliptin) - CARMELINA CV outcomes
Type 2 Diabetes
FDA Approval announced June 4, 2019.
Galcanezumab
Cluster headache
Phase 3 top-line data due 2021.
Mirikizumab (LY3074828)
Ulcerative Colitis
Phase 3 data noted 12% reduction in MACE - June 9, 2019.
Trulicity REWIND CV outcomes
Type 2 diabetes
Phase 3 trial met primary endpoint of non-inferiority.
Tradjenta (linagliptin) - CAROLINA CV outcomes
Type 2 Diabetes
Phase 2 data due 2020.
DONANEMAB N3pG Antipody
Alzheimer's disease
Phase 3 data due 2021.
Abemaciclib (Verzenio) - MonarchE
Breast cancer - adjuvant
Phase 3 data due 2020.
Mirikizumab
Psoriasis
Phase 3 data due 2020.
Baricitinib
Alopecia Areata
Phase 3 data due 2021.
Baricitinib
Systemic lupus erythematosus (SLE)
Phase 3 top-line data did not meet primary endpoint - October 16, 2019.
AM0010 (PEG-IL-10) - Sequoia
Pancreatic ductal adenocarcinoma (PDAC)
Phase 2 trial will completed by year-end 2019 with data disclosure in 2020.
AM0010 (PEG-IL-10) and Pembrolizumab - Cypress 1
Non-small cell lung cancer (NSCLC)
Phase 2 trial will completed by year-end 2019 with data disclosure in 2020.
AM0010 (pegilodecakin) and Nivolumab - Cypress 2
Non-small cell lung cancer (NSCLC)
Phase 1/2 presentation at ASH December 8, 2019 noted CLL 77% ORR; MCL 50% ORR.
LOXO-305
Refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), non-Hodgkin’s lymphomas (NHL)
Phase 3 data released January 18, 2018 did not meet primary endpoint. FDA had already awarded accelerated approval.
LARTRUVO (olaratumab)
Soft tissue sarcoma (STS)
Phase 3 data released April 22, 2019 met primary endpoint. Regulatory filing planned later in 2019.
Taltz (Ixekizumab)
Non-radiographic axial spondyloarthritis
Phase 3 data due 2021.
Tirzepatide - Surpass
Type 2 Diabetes
Phase 3 data due 2022.
Mirikizumab
Crohn's disease
Phase 3 data due 2021.
Dulaglutide
Type 2 diabetes
NDA acceptance announced June 4, 2019. PDUFA date not announced. Estimate April 3, 2020 using 10-month timeline.
Empagliflozin, linagliptin and metformin - triple combo
Type 2 Diabetes
Phase 3 trial met primary and key secondary endpoints - December 17, 2018.
Taltz (Ixekizumab) and adalimumab
Psoriatic Arthritis
FDA Approval announced July 24, 2019.
BAQSIMI (glucagon)
Severe hypoglycemia in people with diabetes
Phase 2 data due 2020.
IL-33
Atopic dermatitis
Phase 2 data due 1H 2020.
D1PAM
Dementia with Lewy bodies (DLB)
Phase 2 data due 2021.
Zagotenemab
Alzheimer's disease
Phase 3 trial met primary endpoint - August 5, 2019.
Galcanezumab
Chronic and episodic migraine
Phase 3 data due 1H 2021.
Solanezumab
Alzheimer's disease
Phase 3 trial initiation announced December 11, 2019.
Selpercatinib (LOXO-292)
Treatment-naïve RET fusion-positive non-small cell lung cancer (NSCLC)

Latest News

  1. Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure

    RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 13, 2019 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) announced today results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to

  2. CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

    INDIANAPOLIS, Dec. 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion

  3. Lilly Opens First Ever Randomized Phase 3 Clinical Trial in Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer

    INDIANAPOLIS, Dec. 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the opening of the LIBRETTO-431 clinical trial [NCT04194944] for selpercatinib, also known as LOXO-292, for treatment-naïve RET

  4. Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting

    INDIANAPOLIS, Dec. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced interim clinical data from the LOXO-305 global Phase 1/2 BRUIN dose escalation trial. LOXO-305 is an investigational, highly

  5. Lilly Announces New Leadership and Strategy in Oncology Research and Development

    INDIANAPOLIS, Dec. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced new leadership and strategic direction in oncology R&D, combining the Lilly Research Laboratories (LRL) oncology

  6. Lilly to Participate in Evercore ISI 2nd Annual HealthCONx Conference

    INDIANAPOLIS, Dec. 2, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019. Daniel Skovronsky, M.D., Ph.D.,

  7. Eli Lilly and Company Unveils Shared Innovation Laboratory in South San Francisco

    INDIANAPOLIS, Dec. 2, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today unveiled its first shared innovation lab, located in South San Francisco, designed to speed the discovery of innovative medicines through

  8. Lilly Names HealthVoyager as Winner of Digital Health Innovation Challenge for Inflammatory Bowel Disease (IBD)

    INDIANAPOLIS, Dec. 2, 2019 /PRNewswire/ -- Eli Lilly and Company's (NYSE:LLY) first digital health open innovation challenge, "Transforming IBD Care: Better Disease Monitoring, Management, and Care for People

  9. Lilly announces $400 million capital investment in manufacturing facilities in Indianapolis

    INDIANAPOLIS, Nov. 20, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced plans to invest $400 million in its manufacturing facilities at its Lilly Technology Center campus in Indianapolis. The plans

  10. Lilly Confirms Date and Conference Call for 2020 Financial Guidance Announcement

    INDIANAPOLIS, Nov. 19, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its financial guidance for 2020 on Tuesday, December 17, 2019. Lilly will also conduct a conference call on that day with the

  11. Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists

    RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 17, 2019 /PRNewswire/ -- A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows

  12. Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes

    RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 13, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 14 to 2 that the benefits of empagliflozin

  13. Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance® in people hospitalized for acute heart failure who have been stabilized

    RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced the initiation of EMPULSE, the sixth phase III study in the Jardiance®

  14. ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz® (ixekizumab) Versus Humira® (adalimumab) Trial in Psoriatic Arthritis

    INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today the 52-week results from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study of Taltz® (ixekizumab) versus Humira® (adalimumab) in

  15. ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis

    INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) presented detailed results today demonstrating Taltz® (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a 52-week

  16. Lilly Reinforces its Commitment to Rheumatology through Data Showcased at the ACR/ARP Annual Meeting

    INDIANAPOLIS, Nov. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that it will present new data from Taltz® (ixekizumab) and Olumiant® (baricitinib) at the American College of Rheumatology

  17. Lilly Announces the Pricing Terms of its Cash Tender Offer for Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities

    INDIANAPOLIS, Nov. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today the pricing terms of its previously announced cash tender offer for up to $2,000,006,000 aggregate principal amount of its

  18. Lilly Announces the Early Tender Results and Upsizing of Its Pending Cash Tender Offer to Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities

    INDIANAPOLIS, Nov. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today the early tender results for its previously announced cash tender offer of its outstanding debt securities.  Lilly also

  19. Lilly to Participate in Credit Suisse 28th Annual Healthcare Conference

    INDIANAPOLIS, Nov. 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Credit Suisse 28th Annual Healthcare Conference on Wednesday, November 13, 2019. Anne White, president of Lilly

  20. Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance®

    - Alliance to focus combined expertise and investment to maximise Jardiance® for people with type 2 diabetes, heart failure, and chronic kidney disease - Alliance to continue to include three product families –

  21. Lilly Reports Strong Third-Quarter 2019 Financial Results, Raises 2019 EPS Guidance

    INDIANAPOLIS, Oct. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced financial results for the third quarter of 2019. $ in millions, except per share data Third

  22. Enrique Conterno, Senior Vice President and President of Lilly Diabetes and Lilly USA, to Retire at End of Year; Mike Mason to Succeed Conterno

    INDIANAPOLIS, Oct. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes and Lilly USA, will retire at the end of

  23. Lilly Declares Fourth-Quarter 2019 Dividend

    INDIANAPOLIS, Oct. 21, 2019 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the fourth quarter of 2019 of $0.645 per share on outstanding common stock. The dividend

  24. Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress

    INDIANAPOLIS, Oct. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that Taltz met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in pediatric patients with

  25. Lilly's REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval

    INDIANAPOLIS, Oct. 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved REYVOW™ (lasmiditan) an oral medication for the acute treatment

  26. Verzenio™ (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study

    Toronto, Oct. 09, 2019 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE:LLY) announced that Verzenio™ (abemaciclib) in combination with fulvestrant significantly extended life by a median of 9.4 months in women with

  27. Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress

    INDIANAPOLIS, Oct. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that it will present new data for Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab at the 28th annual European

  28. Lilly's CYRAMZA® (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology

    INDIANAPOLIS, Oct. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that results from the global Phase 3 RELAY trial of CYRAMZA® (ramucirumab) in previously untreated patients with metastatic

  29. Lilly Announces Voluntary Delisting from Euronext Paris

    INDIANAPOLIS, Oct. 3, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that it has requested the delisting of its shares (ISIN US5324571083) ("Lilly Shares") from Euronext Paris due to the

  30. New Head-to-Head Data Show Taltz® (ixekizumab) Superiority versus TREMFYA® (guselkumab) in People with Moderate to Severe Plaque Psoriasis

    INDIANAPOLIS, Oct. 3, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today presented detailed data at the 5th Annual Maui Derm NP+PA Fall meeting from the Phase 4 IXORA-R study, the first head-to-head (H2H) study

  31. Lilly Confirms Date and Conference Call for Third-Quarter 2019 Financial Results Announcement

    INDIANAPOLIS, Oct. 2, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its third-quarter 2019 financial results on Wednesday, October 23, 2019. Lilly will also conduct a conference call on that day

  32. Verzenio® (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study

    INDIANAPOLIS, Sept. 29, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced Verzenio® (abemaciclib) in combination with fulvestrant significantly extended life by a median of 9.4 months in women with

  33. Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated RET-Altered Thyroid Cancers

    INDIANAPOLIS, Sept. 29, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral selpercatinib1 monotherapy, also known

  34. Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers

    NetworkNewsWire Editorial Coverage: Advances in biotechnology look to deliver promising new treatment options against breast cancer. Independent researchers have found that Genprex Inc.'s (NASDAQ:GNPX) (GNPX Profile)

  35. Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers

    NEW YORK, Sept. 24, 2019 /PRNewswire/ -- Advances in biotechnology look to deliver promising new treatment options against breast cancer.  Independent researchers have found that Genprex Inc.'s (NASDAQ:GNPX) (GNPX

  36. Lilly Oncology to Present Robust Data across Its Growing Portfolio at ESMO 2019

    INDIANAPOLIS, Sept. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced data from a number of studies across the company's oncology product portfolio will be presented at the European Society

  37. CHMP Issues Positive Opinion to Expand Trulicity® (dulaglutide) Label to Include Results from REWIND Cardiovascular Outcomes Trial

    INDIANAPOLIS, Sept. 20, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion

  38. Lilly Announces Webcast to Discuss ESMO 2019 Presentations

    INDIANAPOLIS, Sept. 19, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will conduct a webcast on Wednesday, October 2, 2019 to discuss the company's presentations at the 2019 European Society for Medical

  39. Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer

    INDIANAPOLIS, Sept. 9, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral selpercatinib[1] monotherapy, also known

  40. Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer

    INDIANAPOLIS, Sept. 9, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral selpercatinib[1] monotherapy, also known

  41. Lilly's Pain Clinical Trial Protocol Selected for FDA Complex Innovative Trial Designs Pilot Meeting Program

    INDIANAPOLIS, Sept. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the U.S. Food and Drug Administration (FDA) has accepted its application to enter the Complex Innovative Trial Designs (CID)

  42. Lilly to Participate in Morgan Stanley Global Healthcare Conference

    INDIANAPOLIS, Sept. 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will attend the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief

  43. Lilly Receives U.S. FDA Approval for Taltz® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

    INDIANAPOLIS, Aug. 26, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80 mg/mL for the treatment of

  44. Arbitration panel rules in favor of Lilly in complaint filed by Adocia

    INDIANAPOLIS, Aug. 22, 2019 /PRNewswire/ -- A Chicago-based arbitration panel has ruled in favor of Eli Lilly and Company (NYSE:LLY) in a claim filed by Adocia S.A. over the companies' prior collaboration on a